About DrugPatentWatch
DrugPatentWatch provides actionable business intelligence on small-molecule drugs
DrugPatentWatch is a valuable resource that offers insights into global drug patents, helping stakeholders like pharmaceutical companies, legal professionals, and researchers stay informed about patent expiration, exclusivity status, and competitive landscapes for pharmaceuticals. The platform provides data on drug patents and litigation histories, detailed patent and generic drug manufacturer information, and alerts on upcoming patent expirations.
For businesses in the pharmaceutical industry, DrugPatentWatch can be instrumental in developing strategic approaches to product development, market entry, and patent strategy. It also provides tools for tracking global patent statuses, analyzing competition, and identifying market opportunities, making it a key asset for informed decision-making in drug lifecycle management.
Use cases for the DrugPatentWatch platform include:
- Branded pharmaceutical global business intelligence and forecasting
- Generic drug and API manufacturer portfolio management
- Wholesalers preventing overstock of off-patent drugs
- Healthcare payer formulary management and budget management
Different plans are available, focusing on general business intelligence, expired patents, and forecasting.
Revisions and Annual Editions
DrugPatentWatch incorporates data directly from the FDA, Patent and Trademark Office, and other US and foreign government sources. Each is updated as frequently as possible — often daily — providing you with fresh information.
For those seeking information on now-expired patents, annual editions provide historic archives dating back to the Hatch-Waxman Act — arguably for as long as generic drugs have existed.
Development
DrugPatentWatch is developed by Yali Friedman, Ph.D.
Dr. Friedman is also publisher of the Journal of Commercial Biotechnology and author of Building Biotechnology, which is used as a course text in dozens of biotechnology programs. He also serves as head of data analytics for Scientific American Custom Media, and was also named one of the 100 most influential people in biotechnology by Scientific American.
Dr. Friedman has strong exposure to leading issues in international biotechnology. He is editor of the Scientific American worldVIEW scorecard, a global biotechnology perspective profiling biotechnology industries and innovation capacity in dozens of countries, and has been invited to participate in biotechnology industry development forums for international groups such as APEC, in Europe, and throughout Asia.
Do you have needs beyond DrugPatentWatch's current offerings? Please contact us.
